Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Earlier treatment 'could delay onset of heart failure'
dog
Lead author Adrian Boswood, professor of veterinary cardiology at the RVC, said thanks to the findings, vets no longer have to adopt a 'watch and wait' approach with suspected preclinical cases of MVD.
RVC: Study highlights need for shift in treatment of preclinical MVD
 
A new study suggests earlier treatment of preclinical mitral valve disease (MVD) can delay the onset of heart failure in dogs. Researchers from the Royal Veterinary College (RVC) say this highlights the need for a shift in the way vets diagnose and manage the disease.

The study, Evaluation of Pimobendan in Cardiomegaly (EPIC), found the drug was able to extend the asymptomatic period by 15 months on average and dogs that received pimobendan lived significantly longer than those receiving a placebo. The findings have been published in the Journal of Veterinary Internal Medicine.

Heart disease is one of the top five causes of death in UK dogs and MVD accounts for 75 per cent of cases.

Lead author Adrian Boswood, professor of veterinary cardiology at the RVC, said thanks to the findings, vets no longer have to adopt a 'watch and wait' approach with suspected preclinical cases of MVD.

"When a typical mitral valve murmur is detected, vets should now investigate further to look for cardiac enlargement. If demonstrated, this suggests the patient will probably benefit from treatment with pimobendan before the onset of clinical signs."

Researchers say the EPIC study, which was designed and run by an independent team and sponsored by Boehringer Ingelheim, is the largest prospective veterinary cardiology study carried out to date and produced data to rival that of human clinical trials. Taking seven years to complete, it involved 360 dogs across 11 countries in four continents.

In light of the findings, the team say vets should now consider testing early for signs of preclinical MVD, and in dogs with cardiomegaly secondary to preclinical MVD, should consider the use of pimobendan to delay the onset of congestive heart failure and extend the asymptomatic period.
 

Image courtesy of RVC

Become a member or log in to add this story to your CPD history

Voting opens for BEVA Council

News Story 1
 Eligible members of BEVA will be able to vote for their Council team until Monday, 17 August 2026. Members will have received an election email on 17 July.

There are five candidates standing for four available places on Council. They are:

  • Alexandre Triguino
  • Angela Jones
  • Beth Bryant
  • Holly Rees
  • Hugh Somerville
Full profiles for each candidate can be found on the BEVA website

Click here for more...
News Shorts
Milk recalled over presence of veterinary medicines

Graham's Family Dairy has issued a recall for its semi-skimmed milk due to the presence of veterinary medicines in the product.

In a risk statement, the Food Standards Agency said the presence of the medicines, including penicillin, make the milk unsafe to consume and 'may be a possible health risk for anyone with an allergy to antibiotics'.

Customers who bought the product are advised to return it to the store of purchase for a full refund.